Latest News

View allAccessAL amyloidosisCAR-TConferencesMPEMyelomaNewsPatient evidenceSin categoríaVideos

The European Commission approves isatuximab + VRd combination therapy for newly diagnosed, transplant ineligible myeloma patients

On 22 January 2025, the European Commission approved an isatuximab combination for the treatment of newly diagnosed myeloma patients who are not eligible for a stem cell transplant in the EU. This follows a positive recommendation from the Committee for Medicinal Product for Human Use (CHMP) in November 2024. The CHMP is the European Medicines Agency’s…

Read more

MPE at ASH 2024: key research and expert insights on myeloma

At the 2024 American Society of Hematology (ASH) Annual Meeting, Myeloma Patients Europe (MPE) interviewed experts about the most interesting studies and abstracts in myeloma and AL amyloidosis research that were presented during the conference. Our series of interviews highlights key findings and their impact on patient care: 🎥 Dr. Laurent Garderet discusses the IFM2017-03…

Read more

MPE Year in Review 2024

Myeloma Patients Europe (MPE) is proud to present its Year in Review 2024, highlighting achievements and milestones that reflect our commitment to improving outcomes and quality of life for myeloma and AL amyloidosis patients. This report showcases MPE’s expanded efforts to represent patient needs in European health policy, generate robust evidence that will improve patient…

Read more

Myeloma and AL amyloidosis ASH 2024 preview

The American Society of Hematology (ASH) Annual Meeting, the world’s largest haematology conference, will take place from 7 – 10 December in San Diego, United States. It is a very exciting event for the myeloma and AL amyloidosis clinical and patient community, with all the results from the latest and most important research being presented.…

Read more

MPE provided feedback on the HTA Implementing Regulation on joint scientific consultations on medical devices and in vitro diagnostic medical devices at Union level

This week MPE provided feedback on the draft of the fifth implementing act (out of six planned to be adopted this year) paving the road for the application of the Health Technology Assessment (HTA) Regulation from 12 January 2025. The fifth implementing act focuses on joint scientific consultations on medical devices and in vitro diagnostic…

Read more

MPE comments on the European Medicines Agency’s policy on the handling of competing interests of scientific committees’ members and experts

Last week Myeloma Patients Europe (MPE) provided feedback, as part of a public consultation, on the new European Medicines Agency (EMA) policy on the handling of competing interests of scientific committees’ members and experts. The new policy increases restrictions for the participation of experts, including patient experts, in the EMA procedures assessing specific medical products.…

Read more
February

March 2026

April
MO
TU
WE
TH
FR
SA
SU
23
24
25
26
27
28
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Events for 1st March
No Events
Events for 2nd March
No Events
Events for 3rd March
No Events
Events for 4th March
No Events
Events for 5th March
No Events
Events for 6th March
No Events
Events for 7th March
No Events
Events for 8th March
No Events
Events for 9th March
No Events
Events for 10th March
No Events
Events for 11th March
No Events
Events for 12th March
No Events
Events for 13th March
No Events
Events for 14th March
No Events
Events for 15th March
No Events
Events for 16th March
No Events
Events for 17th March
No Events
Events for 18th March
No Events
Events for 19th March
No Events
Events for 20th March
No Events
Events for 21st March
No Events
Events for 22nd March
No Events
Events for 23rd March
No Events
Events for 24th March
No Events
Events for 25th March
No Events
Events for 26th March
No Events
Events for 27th March
No Events
Events for 28th March
No Events
Events for 29th March
No Events
Events for 30th March
No Events
Events for 31st March
No Events